Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler

Key Points

• Piper Sandler raised Compass Therapeutics’ price target to $6.00 from $4.00 and maintained an “overweight” rating, implying approximately 180% upside from the stock’s $2.15 price.
• Analyst sentiment is broadly positive, with MarketBeat reporting a “Moderate Buy” consensus and an average price target of $11.77, despite targets ranging from $6.00 to $30.00 and one sell rating.
• Compass Therapeutics shares rose 7.8% to $2.15, while the company reported a quarterly loss of $0.13 per share, missing estimates by $0.02; institutional investors own 68.43% of the stock.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) had its price objective lifted by analysts at Piper Sandler from $4.00 to $6.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's target price would suggest a potential upside of 179.72% from the company's current price.

Other research analysts also recently issued reports about the company. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research note on Monday, June 1st. HC Wainwright reissued a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Compass Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $11.77.

Compass Therapeutics Trading Up 7.8%

NASDAQ CMPX traded up $0.15 during trading hours on Friday, reaching $2.15. The company's stock had a trading volume of 2,131,049 shares, compared to its average volume of 4,718,508. The business has a 50-day simple moving average of $2.10 and a 200 day simple moving average of $3.88. Compass Therapeutics has a 52 week low of $1.61 and a 52 week high of $6.88. The stock has a market cap of $386.29 million, a PE ratio of -5.21 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities analysts predict that Compass Therapeutics will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Simplicity Wealth LLC bought a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $80,000. Bank of New York Mellon Corp bought a new position in shares of Compass Therapeutics in the second quarter valued at approximately $769,000. State of Wyoming bought a new position in shares of Compass Therapeutics in the second quarter valued at approximately $31,000. GSA Capital Partners LLP acquired a new position in shares of Compass Therapeutics during the second quarter valued at approximately $154,000. Finally, Walleye Trading LLC acquired a new position in shares of Compass Therapeutics during the second quarter valued at approximately $55,000. Institutional investors own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source